Publications

de Bono, JS., Logothetis, CJ., Molina, A., Fizazi, K., North, S., Chu, L., Chi, KN., Jones, RJ., Goodman, OB., Saad, F., et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, Vol.364(21), pp.1995-2005,  Show Abstract

de Bono, JS., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, JP., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, MJ., Shen, L., et al. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, Vol.376(9747), pp.1147-1154,  Show Abstract

Fong, PC., Boss, DS., Yap, TA., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, MJ., et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med, Vol.361(2), pp.123-134,  Show Abstract

Attard, G., Reid, AH., Yap, TA., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol, Vol.26(28), pp.4563-4571,  Show Abstract

Yap TA, ., Olmos, D., Brunetto AT, ., Tunariu N, ., Barriuso J, ., Riisnaes R, ., Pope L, ., Clark J, ., Futreal A, ., Germuska M, ., et al. () Phase I Trial of a Selective c-MET Inhibitor ARQ197 Incorporating Proof of Mechanism Pharmacodynamic Studies. J Clin Oncol 2011,

De Bono, JS., Scher, H., Fizazi, K., Saad F, ., Taplin, M., Sternberg, C., Miller, K., de Wit, R., Mulders, P., Chi, K., et al. () Increased Survival with Enzalutamide in Prostate Cancer New England Journal of Medicine,